SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Apricus Biosciences
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: phoenix_rising who wrote (1586)12/16/2015 2:11:25 AM
From: Mirror Image  Read Replies (1) of 2026
 
The 3Q 15' 10Q has Apricus selling the product only to two partners directly: Takeda and Sandoz. Takeda sells Vitaros in the U.K. and Sandoz is currently selling Vitaros in 3 countries: Sweden, Luxemburg and Belgium.

Both Majorelle and Recordati have direct agreements with the manufacturer.

During the third quarter of 2015, Groupe Parima began manufacturing product for Recordati under its own manufacturing and supply agreement. Recordati launched the product as Virirec™ in Spain in May 2015.

During the first quarter of 2015, Groupe Parima began manufacturing product for Majorelle under its own manufacturing and supply agreement.

It says nothing about having a supply agreement with Bracco.

So, given this information, do you think we have $8.3 M in open purchase orders for Vitaros from Takeda and Sandoz? Remember just how many units we were selling when it was only those two specific partners at the market? Not many. Not to mention Vitaros was being sold in Germany back then and is not at this current time.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News